Two epilepsy drugs – Lamictal and Keppra – which are currently listed in category C may be dangerous to a fetus and should be listed in category D, according to new data. The difference between the categories is that D shows evidence of risk, but the benefits outweigh the risks…
To say the word “Keppra,” is to invite instant controversy. For some people it works, for some it doesn’t and for others, it’s a living nightmare.
Yet two different studies found that clinically significant behavioral consequences of Keppra were eight percent, no higher, and maybe even lower, than those reported for other new antiepileptic drugs.
John Gates, M.D., lead investigator of the adult study, neurologist at Minnesota Epilepsy Group and clinical professor of neurology at the University of Minnesota said: “The efficacy of Keppra in treating seizures, coupled with our findings of its low side-effect profile, makes it an option that should be considered, especially for those who have struggled with other treatments.”
Interestingly, both studies evaluated patients with epilepsy who were proven to be drug resistant to other medications.
People with epilepsy are more than twice as likely to develop migraine headaches as those without the disorder. In fact, research showed that more than 20 percent of people with epilepsy have migraines, compared to 11 percent of the general population.
In one epilepsy study, about 16% of those people who had migraines also experienced epileptic seizures before, during or after a migraine…
“All patients who are currently taking or starting on any anti-epileptic drug should be closely monitored for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression,” the FDA warned in a letter to health professionals…
Keppra — which is a brand name seizure medication — was approved in 2009… Patients that were then switched to Levetiracetam are now experiencing on-going seizures that did not occur while they were on the drug Keppra.